The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis

By Lindberg R.L.P.  

Brain, Vol. 124, Iss. 9, 2001-09 ,pp. : 1743-1753

Oxford University Press

Access to resources Recommend Favorite

Neutralizing antibodies against IFN‐ in multiple sclerosis: antagonization of IFN‐ mediated suppression of MMPs

By  

Brain, Vol. 127, Iss. 2, 2004-02 ,pp. : 259-268

Oxford University Press

Access to resources Recommend Favorite

Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis

By Longbrake Erin   Parks Becky   Cross Anne  

Current Neurology and Neuroscience Reports, Vol. 13, Iss. 11, 2013-11 ,pp. : 1-9

Springer Publishing Company

Access to resources Recommend Favorite

Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis

By Diem Ricarda  

Brain, Vol. 128, Iss. 2, 2005-02 ,pp. : 375-385

Oxford University Press

Access to resources Recommend Favorite

Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis

By Opdenakker G.   Nelissen I.   Van Damme J.  

Lancet Neurology, Vol. 2, Iss. 12, 2003-12 ,pp. : 747-756

Elsevier

Access to resources Recommend Favorite